Johns Hopkins University School of Medicine and Johns Hopkins University Bloomberg School of Public Health, 5501 Hopkins Bayview Circle, Baltimore, MD 21224,USA.
Curr Opin Pulm Med. 2012 Jan;18(1):48-56. doi: 10.1097/MCP.0b013e32834db0f2.
Over the past decade, the concept of asthma control as distinct from asthma severity has been clearly defined. Well controlled asthma is the goal of therapy in all asthma patients. This review is a comprehensive description of the tools currently available for a methodical assessment of different aspects of asthma control in clinical practice and research.
Several questionnaires for assessing asthma control have been extensively validated in adults. In children, validation data are less extensive. Considerable overlap exists between asthma control measures and measures of asthma-specific quality of life. Asthma-specific quality-of-life questionnaires have been used as primary outcome measures in major clinical trials evaluating asthma therapy. Biomarkers that reflect eosinophilic inflammation of the airways are used as intermediate outcome measures to reflect the biological basis of asthma control. There is some controversy, however, over which biomarkers are best incorporated into therapeutic algorithms that attempt to achieve maximal asthma control while minimizing treatment intensity.
In designing clinical studies to evaluate different asthma therapies, researchers will find this review to be a useful resource in terms of choosing the appropriate tool for assessing asthma control. This is also a valuable resource for a methodical assessment of response to asthma therapy in routine clinical care.
在过去的十年中,哮喘控制的概念与哮喘严重程度明显区分开来。所有哮喘患者的治疗目标都是控制良好的哮喘。这篇综述全面描述了目前可用于临床实践和研究中系统评估哮喘控制不同方面的工具。
已经在成人中广泛验证了几种评估哮喘控制的问卷。在儿童中,验证数据则不那么广泛。哮喘控制措施与哮喘特定生活质量措施之间存在很大的重叠。哮喘特异性生活质量问卷已被用作评估哮喘治疗的主要临床试验的主要结局指标。反映气道嗜酸性炎症的生物标志物被用作中间结局指标,以反映哮喘控制的生物学基础。然而,关于哪些生物标志物最适合纳入试图在最大限度地控制哮喘的同时最小化治疗强度的治疗算法,存在一些争议。
在设计评估不同哮喘疗法的临床研究时,研究人员将发现这篇综述是选择评估哮喘控制的适当工具的有用资源。这也是评估常规临床护理中对哮喘治疗反应的系统方法的有价值资源。